Neuregulin-1β is associated with disease severity and adverse outcomes in chronic heart failure

Circulation

Volumn 120, Issue 4, 2009, Pages 310-317

  Ky, Bonnie ^a   Kimmel, Stephen E ^a   Safa, Radwan N ^b   Putt, Mary E ^a   Sweitzer, Nancy K ^c   Fang, James C ^d   Sawyer, Douglas B ^e   Cappola, Thomas P ^a,f  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f 6 Penn Tower ^*  (United States)

Author keywords

Cardiomyopathy; Heart failure; Neuregulin 1

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BRAIN NATRIURETIC PEPTIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GROWTH FACTOR; NEUREGULIN 1 BETA; UNCLASSIFIED DRUG;

ADULT; ADVERSE OUTCOME; ARTICLE; CARDIOMYOPATHY; COLOR ULTRASOUND FLOWMETRY; CONFIDENCE INTERVAL; DEATH; DISEASE SEVERITY; FEMALE; FOLLOW UP; HAZARD RATIO; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STRATIFICATION; SURVIVAL; SYSTOLIC HEART FAILURE; TRANSTHORACIC ECHOCARDIOGRAPHY; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

ADULT; AGED; BIOLOGICAL MARKERS; CHRONIC DISEASE; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; NEUREGULIN-1; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 68249087127     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.856310     Document Type: Article

References (40)

1. Falls DL. Neuregulins: functions, forms, and signaling strategies. Exp Cell Res. 2003;284:14 -30.
2. Zhao YY, Sawyer DR, Baliga RR, Opel DJ, Han X, Marchionni MA, Kelly RA. Neuregulins promote survival and growth of cardiac myocytes: persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem. 1998;273:10261-10269.
3. Garratt AN. "To erb-B or not to erb-B." Neuregulin-1/ErbB signaling in heart development and function. J Mol Cell Cardiol. 2006;41:215-218.
4. Chien KR. Herceptin and the heart: a molecular modifier of cardiac failure. N Engl J Med. 2006;354:789 -790.
5. Meyer D, Birchmeier C. Multiple essential functions of neuregulin in development. Nature. 1995;378:386 -390.
6. Kramer R, Bucay N, Kane DJ, Martin LE, Tarpley JE, Theill LE. Neuregulins with an Ig-like domain are essential for mouse myocardial and neuronal development. Proc Natl Acad Sci U S A. 1996;93: 4833-4838.
7. Liu X, Hwang H, Cao L, Buckland M, Cunningham A, Chen J, Chien KR, Graham RM, Zhou M. Domain-specific gene disruption reveals critical regulation of neuregulin signaling by its cytoplasmic tail. Proc Natl Acad Sci U S A. 1998;95:13024 -13029.
8. Liu FF, Stone JR, Schuldt AJ, Okoshi K, Okoshi MP, Nakayama M, Ho KK, Manning WJ, Marchionni MA, Lorell BH, Morgan JP, Yan X. Heterozygous knockout of neuregulin-1 gene in mice exacerbates doxorubicin-induced heart failure. Am J Physiol Heart Circ Physiol. 2005;289:H660-H666.
9. Ozcelik C, Erdmann B, Pilz B, Wettschureck N, Britsch S, Hubner N, Chien KR, Birchmeier C, Garratt AN. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A. 2002;99:8880-8885.
10. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, Peterson KL, Chen J, Kahn R, Condorelli G, Ross J Jr, Chien KR, Lee KF. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med. 2002;8: 459-465.
11. Liu X, Gu X, Li Z, Li X, Li H, Chang J, Chen P, Jin J, Xi B, Chen D, Lai D, Graham RM, Zhou M. Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol. 2006;48:1438 -1447.
12. Peng X, Chen B, Lim CC, Sawyer DB. The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine. Mol Interv. 2005;5:163-171.
13. Cote GM, Miller TA, Lebrasseur NK, Kuramochi Y, Sawyer DB. Neuregulin-1alpha and beta isoform expression in cardiac microvascular endothelial cells and function in cardiac myocytes in vitro. Exp Cell Res. 2005;311:135-146.
14. Vorovich E, Chuai S, Li M, Avena J, Marwin M, Wolfe D, Reilly MP, Cappola TP. Comparison of MMP-9 and BNP as clinical biomarkers in chronic heart failure. Am Heart J. 2008;50:992-997.
15. Hunt SA, American College of Cardiology, American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005; 46:e1- e82.
16. Astor BC, Yi S, Hiremath L, Corbin T, Pogue V, Wilkening B, Peterson G, Lewis J, Lash JP, Van Lente F, Gassman J, Wang X, Bakris G, Appel LJ, Contreras G. N-terminal prohormone brain natriuretic peptide as a predictor of cardiovascular disease and mortality in blacks with hypertensive kidney disease: the African American Study of Kidney Disease and Hypertension (AASK). Circulation. 2008;117:1685-1692.
17. Bibbins-Domingo K, Gupta R, Na B, Wu AH, Schiller NB, Whooley MA. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA. 2007;297:169 -176.
18. Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol. 1989;129:125-137.
19. Sun GW, Shook TL, Kay GL. Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. J Clin Epidemiol. 1996;49:907-916.
20. Lemmens K, Doggen K, De Keulenaer GW. Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure. Circulation. 2007;116:954 -960.
21. Hunter JJ, Chien KR. Signaling pathways for cardiac hypertrophy and failure. N Engl J Med. 1999;341:1276 -1283.
22. Kaye DM, Hoshijima M, Chien KR. Reversing advanced heart failure by targeting Ca2+ cycling. Annu Rev Med. 2008;59:13-28.
23. Kittleson MM, Minhas KM, Irizarry RA, Ye SQ, Edness G, Breton E, Conte JV, Tomaselli G, Garcia JG, Hare JM. Gene expression analysis of ischemic and nonischemic cardiomyopathy: shared and distinct genes in the development of heart failure. Physiol Genomics. 2005;21:299 -307.
24. Cohn JN. The management of chronic heart failure. N Engl J Med. 1996;335:490-498.
25. Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008;358: 2148-2159.
26. Lainchbury JG, Richards AM, Nicholls MG, Hunt PJ, Ikram H, Espiner EA, Yandle TG, Begg E. The effects of pathophysiological increments in brain natriuretic peptide in left ventricular systolic dysfunction. Hypertension. 1997;30:398-404.
27. Kuramochi Y, Cote GM, Guo X, Lebrasseur NK, Cui L, Liao R, Sawyer DB. Cardiac endothelial cells regulate reactive oxygen species-induced cardiomyocyte apoptosis through neuregulin-1beta/erbB4 signaling. J Biol Chem. 2004;279:51141-51147.
28. Chen B, Peng X, Pentassuglia L, Lim CC, Sawyer DB. Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovasc Toxicol. 2007;7:114 -121.
29. Rentschler S, Morley GE, Fishman GI. Molecular and functional maturation of the murine cardiac conduction system. Cold Spring Harb Symp Quant Biol. 2002;67:353-361.
30. Lemmens K, Fransen P, Sys SU, Brutsaert DL, De Keulenaer GW. Neuregulin-1 induces a negative inotropic effect in cardiac muscle: role of nitric oxide synthase. Circulation. 2004;109:324 -326.
31. Kuramochi Y, Guo X, Sawyer DB. Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. J Mol Cell Cardiol. 2006;41:228 -235.
32. Hertig CM, Kubalak SW, Wang Y, Chien KR. Synergistic roles of neuregulin-1 and insulin-like growth factor-I in activation of the phosphatidylinositol 3-kinase pathway and cardiac chamber morphogenesis. J Biol Chem. 1999;274:37362-37369.
33. Rohrbach S, Niemann B, Silber RE, Holtz J. Neuregulin receptors erbB2 and erbB4 in failing human myocardium: depressed expression and attenuated activation. Basic Res Cardiol. 2005;100:240 -249.
34. Uray IP, Connelly JH, Thomazy V, Shipley GL, Vaughn WK, Frazier OH, Taegtmeyer H, Davies PJ. Left ventricular unloading alters receptor tyrosine kinase expression in the failing human heart. J Heart Lung Transplant. 2002;21:771-782.
35. Perik PJ, de Vries EG, Gietema JA, van der Graaf WT, Smilde TD, Sleijfer DT, van Veldhuisen DJ. Serum HER2 levels are increased in patients with chronic heart failure. Eur J Heart Fail. 2007;9:173-177.
36. Ban K, Cooper AJ, Samuel S, Bhatti A, Patel M, Izumo S, Penninger JM, Backx PH, Oudit GY, Tsushima RG. Phosphatidylinositol 3-kinase gamma is a critical mediator of myocardial ischemic and adenosine-mediated preconditioning. Circ Res. 2008;103:643- 653.
37. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, Glazer RD, Tognoni G, Cohn JN, Val-HeFT Investigators. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2003;107:1278 -1283.
38. Masson S, Latini R, Anand IS, Vago T, Angelici L, Barlera S, Missov ED, Clerico A, Tognoni G, Cohn JN, Val-HeFT Investigators. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem. 2006;52:1528 -1538.
39. Tang WH, Girod JP, Lee MJ, Starling RC, Young JB, Van Lente F, Francis GS. Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation. 2003;108:2964 -2966.
40. LeBrasseur NK, Mizer KC, Parkington JD, Sawyer DB, Fielding RA. The expression of neuregulin and erbB receptors in human skeletal muscle: effects of progressive resistance training. Eur J Appl Physiol. 2005;94: 371-375.